Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705028 | 0.85 | POLB (0.57) | NPY1RNPY2RSLC6A4HTR6HTR2C | |
| SCHEMBL130569 | 0.83 | PDE4A (0.55) | NPY1RNPY2RPDE4DPOLB | |
| SCHEMBL682485 | 0.82 | POLB (0.57) | NPY1RNPY2RSLC6A4HTR6HTR2C | |
| SCHEMBL28009643 | 0.81 | TSHR (0.41) | — | |
| SCHEMBL129356 | 0.80 | PDE4A (0.59) | NPY1RNPY2RPDE4DPOLB | |
| SCHEMBL29340248 | 0.80 | NPY1R (0.49) | NPY1RNPY2RSLC6A4PDE4D | |
| SCHEMBL5704271 | 0.78 | PDE4A (0.57) | NPY1RNPY2RPDE4DPOLB | |
| SCHEMBL5252344 | 0.77 | KDM4E (0.45) | SLC6A4POLB | |
| SCHEMBL31096114 | 0.76 | PDE4A (0.50) | NPY1RNPY2RSLC6A4HTR6PDE4D | |
| SCHEMBL133005 | 0.76 | PDE4A (0.50) | NPY1RNPY2RSLC6A4HTR6PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | NPY1R 378/4885NPY2R 332/4885SLC6A4 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.